475 related articles for article (PubMed ID: 31824502)
21. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.
Nishimoto KP; Barca T; Azameera A; Makkouk A; Romero JM; Bai L; Brodey MM; Kennedy-Wilde J; Shao H; Papaioannou S; Doan A; Masri C; Hoang NT; Tessman H; Ramanathan VD; Giner-Rubio A; Delfino F; Sharma K; Bray K; Hoopes M; Satpayev D; Sengupta R; Herrman M; Abbot SE; Aftab BT; An Z; Panuganti S; Hayes SM
Clin Transl Immunology; 2022; 11(2):e1373. PubMed ID: 35136603
[TBL] [Abstract][Full Text] [Related]
22. A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy.
Ferry GM; Agbuduwe C; Forrester M; Dunlop S; Chester K; Fisher J; Anderson J; Barisa M
Front Immunol; 2022; 13():863155. PubMed ID: 35711450
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.
Bryant NL; Gillespie GY; Lopez RD; Markert JM; Cloud GA; Langford CP; Arnouk H; Su Y; Haines HL; Suarez-Cuervo C; Lamb LS
J Neurooncol; 2011 Jan; 101(2):179-88. PubMed ID: 20532954
[TBL] [Abstract][Full Text] [Related]
24. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells.
Shrestha B; Zhang Y; Yu B; Li G; Boucher JC; Beatty NJ; Tsai HC; Wang X; Mishra A; Sweet K; Lancet JE; Kelley L; Davila ML
J Immunother; 2020 Apr; 43(3):79-88. PubMed ID: 31834208
[TBL] [Abstract][Full Text] [Related]
25. Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma.
Fowler D; Barisa M; Southern A; Nattress C; Hawkins E; Vassalou E; Kanouta A; Counsell J; Rota E; Vlckova P; Draper B; De Mooij T; Farkas A; Brezovjakova H; Baker AT; Scotlandi K; Manara MC; Tape C; Chester K; Anderson J; Fisher J
Sci Transl Med; 2024 May; 16(749):eadg9814. PubMed ID: 38809963
[TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
27. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
[TBL] [Abstract][Full Text] [Related]
28. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
29. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
Gogoi D; Chiplunkar SV
Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
32. Dendritic Cells Are Critical for the Activation and Expansion of Vδ2
Wang X; Liu J; Gao H; Mo XD; Han T; Xu LP; Zhang XH; Huang XJ
Front Immunol; 2018; 9():2528. PubMed ID: 30443256
[TBL] [Abstract][Full Text] [Related]
33. Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells.
Halary F; Pitard V; Dlubek D; Krzysiek R; de la Salle H; Merville P; Dromer C; Emilie D; Moreau JF; Déchanet-Merville J
J Exp Med; 2005 May; 201(10):1567-78. PubMed ID: 15897274
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
35. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
36. Human and murine memory γδ T cells: Evidence for acquired immune memory in bacterial and viral infections and autoimmunity.
Comeau K; Paradis P; Schiffrin EL
Cell Immunol; 2020 Nov; 357():104217. PubMed ID: 32979762
[TBL] [Abstract][Full Text] [Related]
37. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
38. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
Kim M; Kim H; Han M; Hwang HJ; Kim H; Im HJ; Kim N; Koh KN
Anticancer Res; 2021 Dec; 41(12):6031-6038. PubMed ID: 34848457
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
